US8808811074 - Common Stock
TERNS PHARMACEUTICALS INC
NASDAQ:TERN (3/27/2024, 8:00:01 PM)
After market: 6.16 0 (0%)6.16
0 (0%)
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 46 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity. Its product pipeline includes TERN-701, TERN-501, TERN-601 and TERN-101. ItsTERN-701 is an oral, potent, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) specifically targeting the ABL myristoyl pocket for chronic myeloid leukemia. The TERN-501 is its highly selective thyroid hormone receptor beta (THR-b) agonist for non-alcoholic steatohepatitis (NASH) in Phase IIa clinical development. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist for metabolic diseases such as obesity. TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver.
TERNS PHARMACEUTICALS INC
1065 East Hillsdale Blvd., Suite 100, Suite 100
Foster City CALIFORNIA 94404
P: 16505255535
CEO: Senthil Sundaram
Employees: 46
Website: https://ternspharma.com/
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
TERN stock results show that Terns Pharma met analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Terns Pharma (NASDAQ:TERN) just reported results for the fourth quarter of 2023...
Here you can normally see the latest stock twits on TERN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: